Ibrutinib (Imbruvica) prior authorization at Regence
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Regence requires prior-authorization documentation for Ibrutinib (Imbruvica): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Regence reviews Ibrutinib (Imbruvica) prior authorizations against its medical policy . Regence-specific context: BCBS licensee operating in Oregon, Washington (Clark/Cowlitz counties), Idaho, and Utah (~3.1M members). Subsidiary of Cambia Health Solutions. Prime Therapeutics PBM. Each state's DOI handles complaints for policies issued in that state.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Regence's medical policy URL referenced in the cover letter
Regence's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Cross-state coordination for multi-state members (OR/WA/ID/UT)
- Step therapy via Prime Therapeutics
- Behavioral health network adequacy
- Specialty drug PA
Ibrutinib (Imbruvica)-specific denial patterns and context
Across payers (not just Regence), Ibrutinib (Imbruvica)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- NCCN compendium use denials
- Combination therapy denial
Brand: Imbruvica. BTK inhibitor used in CLL, MCL, marginal-zone lymphoma, GvHD.
Manufacturer patient-assistance program: Pharmacyclics PAP — relevant when a Regence denial sticks and the patient needs bridge access while appealing.
If the PA is denied
Regence gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.regence.com/provider) with the same packet plus a peer-reviewed citation supporting Ibrutinib (Imbruvica)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Regence denial on DenialHelp.
Contact Regence
- Provider portal: https://www.regence.com/provider
Frequently asked questions
What documentation does Regence need for Ibrutinib (Imbruvica) prior auth?
Regence's typical PA packet for Ibrutinib (Imbruvica): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Regence?
Standard Ibrutinib (Imbruvica) PA decisions at Regence: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Regence most often reject Ibrutinib (Imbruvica) for?
Across Regence's book the common rejection patterns include: Cross-state coordination for multi-state members (OR/WA/ID/UT); Step therapy via Prime Therapeutics; Behavioral health network adequacy. For Ibrutinib (Imbruvica) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with Regence on Ibrutinib (Imbruvica)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Ibrutinib (Imbruvica) PA packet
Open ApprovalHelp — generate a Ibrutinib (Imbruvica) prior-auth packet tailored to Regence's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com